Home / GU oncology / Testis / Stage I GCT

Testis → Clinical stage I germ-cell tumor

Last reviewed: 2026-09-22 · Next review: 2026-12-21

current — surveillance is preferred when reliable follow-up is feasible; adjuvant treatment reduces relapse but does not establish a survival advantage over surveillance

Evidence page

Who this applies to

PopulationDefinitionBoundary
Clinical stage I seminomaPure seminoma after orchiectomy, normalizing markers, and no metastasis on conventional staging45.Elevated AFP should be managed as nonseminoma/mixed GCT, not pure seminoma4.
Clinical stage I NSGCTNegative conventional staging with normalized post-orchiectomy markers45.Persistently rising AFP or hCG is occult systemic disease, not a surveillance/adjuvant population4.
Shared requirementsFertility preservation, contralateral testis assessment, pathology review, and follow-up feasibility45.IGCCCG prognosis groups apply to metastatic disease, not stage I4.

Standard options

Clinical contextOptionKey inclusionTypical course
Stage I seminomaSurveillance24Feasible cross-sectional imaging and marker follow-up24.Guideline-directed surveillance46.
Stage I seminoma selecting adjuvant therapyOne carboplatin AUC 7 cycle1Recurrence-reduction option after shared decision-making14.One cycle1.
Stage I NSGCT, especially LVI-positive or surveillance unsuitableOne BEP cycle3LVI is the best-validated relapse risk factor4.One cycle3.
Highly selected stage I NSGCTPrimary nerve-sparing RPLND34Specialist-center surgery; consider contraindication to chemotherapy or teratoma with somatic-type malignancy45.Procedure plus structured surveillance4.

Therapy sequencing

Post-orchiectomy settingTreatment orderEvidence boundary
Stage I seminoma with reliable follow-upSurveillance24.Adjuvant carboplatin reduces relapse but does not establish a survival advantage over surveillance14.
Stage I seminoma selecting relapse reductionOne carboplatin AUC 7 cycle → structured surveillance1.TE19 compares carboplatin with radiotherapy, not surveillance1.
Stage I NSGCT, especially LVI-positive or surveillance unsuitableOne BEP cycle → structured surveillance3.The cited randomized trial compares one BEP cycle with RPLND, not either approach with surveillance3.
Highly selected NSGCTPrimary nerve-sparing RPLND → structured surveillance or pathology-directed management34.Center expertise and pathology matter; do not apply an RPLND strategy to seminoma4.

Surveillance and treatment de-escalation

#### Seminoma CS I (surveillance or after adjuvant carboplatin/RT)4

ModalityYear 1Year 2Year 3Years 4–5After 5 years
Tumour markers ± visit42×2×2×1×Survivorship plan4
Chest X-ray4—————
Abdominopelvic MRI/CT42×2×Once at 36 moOnce at 60 mo—

#### NSGCT CS I on active surveillance4

ModalityYear 1Year 2Year 3Years 4–5After 5 years
Tumour markers ± visit44× (minority suggest 6× if LVI+)44×2×1–2×Survivorship plan4
Chest X-ray42×2×Once if LVI+At 60 mo if LVI+—
Abdominopelvic MRI/CT42×At 24 mo (+18 mo if LVI+ per majority)4Once at 36 moOnce at 60 mo—
PhaseStop, hold, or de-escalateRe-escalation / next line
Surveillance (preferred when feasible)24No further adjuvant treatment after orchiectomy when surveillance selected4.Marker rise or imaging relapse → BEP or EP per metastatic/stage II pathway; refer to germ-cell center46.
One-cycle adjuvant (carboplatin or BEP)13Single adjuvant cycle completes treatment; do not extend without relapse13. Markers and imaging per EAU post-adjuvant schedules above4.Relapse → standard metastatic GCT chemotherapy per IGCCCG group4.
  • Adjuvant carboplatin or one BEP reduces relapse but does not establish survival benefit over surveillance in the cited trials13.
Stage I GCT published relapse-free landmarks

Published landmark relapse-free rates only (TE19 5-year RFS; AH 01/94 2-year RFS); not full KM reconstructions; TE19 compared carboplatin with adjuvant RT, not surveillance13.

Landmark evidence

TrialPopulationInterventionComparatorPrimary endpointClinically meaningful outcomesGeneralizability-critical differences
TE19/EORTC 30982, N=1,447Unselected stage I seminoma1Carboplatin AUC 71Adjuvant radiotherapy1Relapse-free rate1Five-year relapse-free rate 94.7% vs 96.0%; HR 1.25 (90% CI 0.83–1.89)1.Does not compare carboplatin with surveillance or prove survival benefit1.
TRISST, N=669Stage I seminoma, normal AFP/hCG, no planned adjuvant therapy2MRI surveillance or reduced scan schedule2CT surveillance or standard scan schedule2Advanced relapse2Six-year advanced relapse 0.6% MRI vs 2.6% CT; five-year OS ≥98% in every arm2.Imaging/surveillance trial, not adjuvant-treatment comparison2.
AH 01/94, N=382Unselected stage I NSGCT3One BEP cycle3RPLND3Two-year recurrence-free survival399.46% vs 91.87%3.Does not compare either strategy with surveillance; RPLND outcomes vary by center expertise3.

Biomarkers

MarkerCurrent clinic roleEmerging / investigationalHow it changes decision nowLimits
Lymphovascular invasion (NSGCT)Best-validated relapse-risk factor for stage I NSGCT4—Favors shared discussion of one BEP vs surveillance when LVI+; EAU estimates relapse about 15% without LVI and up to 50% with LVI34.Shared decision, not a survival mandate for adjuvant therapy4.
Tumor size / rete testis invasion (seminoma)Prognostic discussion only5—May inform counseling intensity; do not use as a stand-alone management rule5.AUA advises against stand-alone management based on these features5.
AFP, hCG, LDHStaging confirmation and surveillance follow-up4—Persistently rising AFP/hCG after orchiectomy is occult systemic disease, not a stage I surveillance/adjuvant population; elevated AFP rules out pure seminoma4.Pre-orchiectomy values alone do not define metastatic IGCCCG groups4.
miR-371a-3pNot standard for surveillance decisions89MAGESTIC and observational cohorts testing relapse detection89Do not replace imaging or standard markers outside a study89.Not practice-ready as a treatment-selection assay on this page89.

Upcoming research

Field direction: miR-371 assays are the main surveillance research track that could change relapse detection and adjuvant decision timing in stage I disease89.

Trial or publicationWhy it may change careEvidence status
MAGESTICTests miR-371 in stage I surveillance and suspected regional disease8.Recruiting phase 2; no treatment-changing outcomes8.
Belge et al.Prospective observational miR-371 surveillance cohort may inform future relapse detection9.Peer-reviewed observational report; not a treatment-selection standard9.

Toxicity

Regimen and comparatorTrial-level safety outcomesSelected named toxicitiesCounseling focus
One BEP versus RPLND, long-term AH 01/94 questionnaireSelected follow-up questionnaire data, not a contemporary regimen-wide estimate3.Peripheral neuropathy 16% vs 12%; retrograde ejaculation 9% vs 24%3.Discuss neuropathy, hearing/renal and pulmonary risks from chemotherapy, and ejaculation/fertility effects from surgery; preserve fertility before treatment34.
Carboplatin or modern adjuvant radiotherapy for stage I seminomaNo eligible primary-paper named-event table >5% was retrieved1.Do not add unverified rates1.Counsel qualitatively on acute treatment effects; radiotherapy has later second-malignancy concern and long-term single-carboplatin safety data remain less mature14.

On-treatment monitoring

SOC/option regimenHallmark monitoring toxicity and available ratePatient action / clinic response
One carboplatin AUC 7 cycleA comparable named-event rate was not retrieved from the eligible primary paper1.Check CBC and renal function and review fever/infection symptoms, bruising/bleeding, nausea/vomiting, and new hearing/neuropathy symptoms; fever, bleeding, or uncontrolled vomiting needs prompt contact14.
One BEP cycleAH 01/94 follow-up questionnaire: peripheral neuropathy 16% vs 12% after RPLND; this is long-term selected follow-up, not a contemporary regimen-wide rate3.Check CBC, renal function, hearing, neuropathy, pulmonary symptoms, and fertility plan; fever, dyspnea, new/worsening numbness, reduced urine output, or severe vomiting needs prompt contact3.
Primary nerve-sparing RPLNDAH 01/94: retrograde ejaculation 24% vs 9% after one BEP cycle3.Review urinary, sexual/ejaculatory, fertility, wound, and thrombotic symptoms; fever, wound concerns, urinary retention, or severe pain needs prompt contact3.
Adjuvant radiotherapy, when selectedA comparable named-event rate was not retrieved from the eligible primary paper1.Review acute bowel, fatigue, and skin symptoms and late survivorship concerns; persistent vomiting, dehydration, severe bowel symptoms, or bleeding needs prompt contact14.

Epic phrase

#stage1gct

  • Counseling: Surveillance is preferred when follow-up is reliable. One carboplatin cycle (TE19): 5-year relapse-free rate about 95% vs 96% with radiotherapy—not versus surveillance; does not prove survival benefit. One BEP vs RPLND (AH 01/94): 2-year recurrence-free survival about 99% vs 92%—does not compare either to surveillance. TRISST: MRI surveillance low advanced-relapse rates with ≥98% 5-year OS in all arms.
  • Counseling: Reviewed surveillance and de-escalation: EAU minimal follow-up—seminoma CS I: markers about twice yearly years 1–3 then yearly years 4–5, abdominopelvic MRI/CT twice yearly years 1–2 then at 36 and 60 months (no routine chest X-ray); NSGCT on surveillance: markers about 4×/year years 1–2 (some use 6× if LVI+), chest X-ray twice yearly years 1–2 (± later if LVI+), abdominopelvic MRI/CT twice in year 1, at 24 months (±18 months if LVI+), then at 36 and 60 months. One adjuvant carboplatin or BEP cycle completes treatment without maintenance; marker rise or imaging relapse → metastatic GCT pathway at a germ-cell center.
  • Counseling: Reviewed sequence: after orchiectomy, surveillance when feasible; one carboplatin cycle then surveillance for seminoma selecting relapse reduction; one BEP cycle then surveillance for higher-risk NSGCT; or selected nerve-sparing RPLND then structured surveillance. ***
  • Monitoring: With carboplatin or BEP, check CBC/renal function and review fever, bleeding, nausea/vomiting, hearing, neuropathy, and pulmonary symptoms; after RPLND, review wound, urinary, sexual/ejaculatory, fertility, and thrombotic symptoms. ***
  • Decision: *** selects surveillance / one carboplatin cycle / one BEP cycle / primary RPLND / referral to germ-cell specialist.
  • Labs/NGS: AFP, hCG, LDH *; post-orchiectomy trend *; staging imaging ***.
  • Procedures: *** sperm banking, pathology review, RPLND consultation.
  • Follow-up: *** guideline-directed marker, imaging, and survivorship surveillance.

Edit markdown

Guideline references

Sources

  1. Oliver et al. (2011). TE19/EORTC 30982. *Journal of Clinical Oncology*. PMID: 21282539
  2. Joffe et al. (2022). TRISST. *Journal of Clinical Oncology*.
  3. Albers et al. (2008). AH 01/94. *Journal of Clinical Oncology*. PMID: 18458040
  4. EAU Testicular Cancer guideline
  5. AUA Early-Stage Testicular Cancer guideline
  6. NCCN Testicular Cancer
  7. ESMO–EURACAN guideline
  8. MAGESTIC
  9. Belge et al. (2023). miR-371 surveillance cohort. PMID: 37967143

Changelog

  • 2026-09-22: Replaced vague surveillance with EAU minimal follow-up tables for seminoma and NSGCT CS I; added published RFS landmark figure; expanded Biomarkers to five-column table; mirrored marker/imaging cadence in paired dotphrase.
  • 2026-09-22: Renamed Upcoming trial results to Upcoming research; reframed for ongoing trials and field direction.
  • 2026-09-22: Named comparator arms in paired dotphrase counseling for efficacy/toxicity rates.
  • 2026-09-22: Added line-level source superscripts ([^n]) linked to numbered Sources.
  • 2026-09-22: Added Surveillance and treatment de-escalation section; strengthened quantified benefit counseling in dotphrase.
  • 2026-09-21: Added stage-I treatment sequencing and monitoring tables for surveillance alternatives, chemotherapy, radiotherapy, and RPLND.
  • 2026-09-21: Created stage I seminoma and NSGCT reference with explicit surveillance, adjuvant, and fertility boundaries.

Edit evidence markdown